Orca-T Earns FDA Priority Review in Heme Malignancies | Targeted Oncology

The FDA has accepted for priority review the biologics license application (BLA) of Orca-T, an investigational allogeneic T-cell immunotherapy, for the treatment of hematologic malignancies including acute myeloid leukemia (AML), acute…